Swiss pharma company, Basilea, receives FDA Qualified Infectious Disease Product designation for fungal drug, isavuconazole
PRESS RELEASE Basilea Pharmaceutica Ltd. announced Thursday that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive More...
Antibiotic candidate, dalbavancin, designated as a Qualified Infectious Disease Product by the FDA
The intravenous antibiotic product candidate, dalbavancin, has been designated as a Qualified Infectious Disease Product (QIDP) by the Food and Drug Administration (FDA), making it eligible for fast-track status, More...
